Bioqual (BIOQ) AI Stock Analysis

• Market Cap: $32.25M
• Dividend Yield: N/A
• Average Volume (3M): 223.00
• Price to Earnings (P/E): ―
• Beta (1Y): -0.13
• Revenue Growth: -14.29%
• EPS Growth: 43.04%
• Country: US
• Employees: 278
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.15
• Shares Outstanding: 893,838
• 10 Day Avg. Volume: 0
• 30 Day Avg. Volume: 223
• PEG Ratio: 0.12
• Price to Book (P/B): 1.11
• Price to Sales (P/S): 0.82
• P/FCF Ratio: 14.87
• Enterprise Value/Market Cap: 2.74
• Enterprise Value/Revenue: 2.41
• Enterprise Value/Gross Profit: -72.82
• Enterprise Value/Ebitda: 32.27
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: $35.00 ▼(-9.68% Downside)
• Action: Reiterated Date: 03/24/26
• Date: Action: Reiterated 03/24/26

The score is held down primarily by deteriorating operating performance (losses, negative gross profit, and multi-year revenue declines). Technicals also remain bearish with the price below all key moving averages and negative MACD, despite oversold readings. Balance sheet and cash flow are comparatively better (positive operating/free cash flow and still-serviceable capitalization), but rising leverage and weaker coverage temper the support.

Positive Factors

Balance Sheet Health

Solid equity and a still-serviceable capital structure give the company durable financial flexibility to fund operations, absorb losses, and pursue recovery initiatives over the next several months. This reduces short-term refinancing pressure and supports strategic options while profitability is restored.

Negative Factors

Multi-year Revenue Decline

Three straight years of revenue decline and a ~26% drop most recently reflect weakening demand or pricing power, a structural risk to long-term recovery. Persistent top-line erosion undermines margins, cash generation and the ability to leverage fixed costs toward sustainable profitability.

Bioqual Business Overview & Revenue Model

Company Description

Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides research services in the areas of COVID-19, AIDS, influenza, RSV infection, and flavivirus i...

Read more

Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides research services in the areas of COVID-19, AIDS, influenza, RSV infection, and flavivirus i...

Bioqual Financial Statement Overview

Breakdown	TTM	Aug 2024	Aug 2023	May 2023	Aug 2021	Aug 2020
Income Statement
Total Revenue	36.68M	48.87M	58.59M	62.66M	66.15M	57.68M
Gross Profit	-1.21M	-1.90M	7.43M	12.60M	13.01M	13.97M
EBITDA	2.74M	509.61K	3.03M	6.97M	14.76M	13.07M
Net Income	702.09K	-1.05M	483.48K	835.55K	5.26M	6.33M
Balance Sheet
Total Assets	72.74M	57.12M	56.59M	61.32M	63.34M	53.42M
Cash, Cash Equivalents and Short-Term Investments	12.34M	17.85M	15.59M	7.28M	2.18M	7.72M
Total Debt	65.68M	16.54M	3.59M	18.61M	18.72M	14.62M
Total Liabilities	36.97M	20.96M	18.94M	23.70M	25.67M	19.89M
Stockholders Equity	35.77M	36.15M	37.65M	37.61M	37.67M	33.53M
Cash Flow
Free Cash Flow	3.95M	2.71M	8.76M	5.99M	-4.57M	-2.26M
Operating Cash Flow	4.31M	2.94M	9.36M	8.23M	313.36K	2.15M
Investing Cash Flow	-6.48M	-238.78K	-597.13K	-2.24M	-4.73M	-3.70M
Financing Cash Flow	0.00	-447.21K	-447.21K	-894.42K	-1.12M	-983.86K

Bioqual Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 38.75
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIOQ, the sentiment is Negative. The current price of 38.75 is above the 20-day moving average (MA) of 36.08, above the 50-day MA of 37.16, and below the 200-day MA of 40.11, indicating a bearish trend. The MACD of -0.27 indicates Negative momentum. The RSI at 20.97 is Positive, neither overbought nor oversold. The STOCH value of 50.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BIOQ.

Bioqual Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BDSX	56 Neutral	$151.42M	-1.46	-302.55%	―	22.29%	31.93%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BNGO	50 Neutral	$12.76M	-0.32	-56.22%	―	-13.84%	88.80%
VNRX	47 Neutral	$26.80M	-1.17	76.82%	―	14.48%	36.83%
BIOQ	46 Neutral	$32.25M	-62.72	-2.84%	―	-14.29%	43.04%
PRPO	46 Neutral	$46.34M	-101.61	-10.07%	―	30.95%	59.67%
NOTV	42 Neutral	$8.92M	-0.17	-44.77%	―	4.54%	47.11%